FIELD: medicine.
SUBSTANCE: method and a kit for treating cancer expressing IGF-1R are disclosed. An anti-IGF-1R antibody and an antibody-drug conjugate of formula Ab-(L-D)n or a pharmaceutically acceptable salt thereof are used.
EFFECT: proposed group of inventions enables to determine the status of IGF-1R cancer by using a first antibody and use a second antibody as ADC (antibody-drug conjugate) for treating cancer.
11 cl, 39 dwg, 18 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
